piperazinyl acetate | 1202064-31-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: piperazinyl acetate
• 英文别名: piperazin-1-yl acetate
• CAS: 1202064-31-0
• 化学式: C₆H₁₂N₂O₂
• 分子量: 144.173
• InChiKey: NHVRYOFWXIIQKV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  piperazinyl acetate 、 2-chloro-4-(4-methoxyphenyl)-6-morpholino-1,3,5-triazine 在 碳酸氢钠 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以55%的产率得到2-(4-acetoxypiperazino)-4-(4-methoxyphenyl)-6-morpholino-1,3,5-triazine
  参考文献：
  名称：

  Synthesis, characterization, and antimicrobial screening of s-triazines linked with piperazine or aniline scaffolds

  摘要：

  摘要：合成了两系列与哌嗪或苯胺骨架连接的三嗪类化合物（4a-i和5a-j），并通过体外方法评估其对革兰氏阳性和革兰氏阴性细菌（克雷伯氏肺炎杆菌MTCC 109、铜绿假单胞菌MTCC 741、金黄色葡萄球菌MTCC 96、蜡样芽孢杆菌MTCC 619）和真菌（白色念珠菌MTCC 183和黑曲霉MTCC 282）的生物活性。对某些细菌和真菌最活跃的化合物为4e、4g、4i、5d和5i。

  DOI：

  10.1515/hc-2013-0077

文献信息

• [EN] 4-ARYL-2-ANILINO-PYRIMIDINES AS PLK KINASE INHIBITORS<br/>[FR] 4-ARYL-2-ANILINO-PYRIMIDINES COMME INHIBITEURS DE PLK KINASES
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2009112439A1

  公开（公告）日：2009-09-17

  The present invention relates to compounds of Formula (Ia) or (Ib), the N-oxide forms, pharmaceutically acceptable addition salts, quaternary amines, stereoisomers, tautomers, racemics, metabolites, prodrugs, hydrates, or solvates thereof, wherein Y1, m, n, R1; X1; X2; R2; X3; X4; R3; and R4 have the meaning defined in the claims. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use in therapy. The invention particularly relates to compounds that are kinase inhibitors useful for the treatment of disease states mediated by kinase, especially PLK4, in particular such compounds that are useful in the treatment of pathological processes which involve an aberrant cellular proliferation, such as tumor growth, rheumatoid arthritis, restenosis and atherosclerosis.

  本发明涉及式(Ia)或(Ib)的化合物，其N-氧化物形式，药学上可接受的加盐物，季铵盐，立体异构体，互变异构体，消旋体，代谢物，前药，水合物或其溶剂化合物，其中Y1，m，n，R1；X1；X2；R2；X3；X4；R3；和R4在权利要求中定义的含义。本发明还涉及制备所述化合物的方法，含有它们的药物组合物以及它们在治疗中的用途。该发明特别涉及激酶抑制剂，用于治疗由激酶介导的疾病状态，特别是PLK4，特别是对治疗涉及异常细胞增殖的病理过程有用的化合物，如肿瘤生长、类风湿关节炎、再狭窄和动脉粥样硬化。
• Isotopically enriched N-substituted piperazine acetic acids and methods for the preparation thereof
  申请人：Dey Subhakar

  公开号：US20050148774A1

  公开（公告）日：2005-07-07

  In some embodiments, this invention pertains to isotopically enriched N-substituted piperazine acetic acids. In some embodiments, this invention pertains to methods for the preparation of isotopically enriched N-substituted piperazine acetic acids.

  在某些实施例中，这项发明涉及同位素富集的N-取代哌嗪乙酸。在某些实施例中，这项发明涉及同位素富集的N-取代哌嗪乙酸的制备方法。
• Mixtures of isobarically labeled analytes and fragments ions derived therefrom
  申请人：Pappin J.C. Darryl

  公开号：US20050147982A1

  公开（公告）日：2005-07-07

  This invention pertains to mixtures of isobarically labeled analytes and fragment ions thereof.

  这项发明涉及等压标记的分析物混合物及其碎片离子。
• Active esters of N-substituted piperazine acetic acids, including isotopically enriched versions thereof
  申请人：Dey Subhakar

  公开号：US20050148771A1

  公开（公告）日：2005-07-07

  In some embodiments, this invention pertains to active esters of N-substituted piperazine acetic acid, including isotopically enriched versions thereof. In some embodiments, this invention pertains to methods for the preparation of active esters of N-substituted piperazine acetic acid, including isotopically enriched versions thereof.

  在某些实施例中，这项发明涉及N-取代哌嗪乙酸的活性酯，包括其同位素富集版本。在某些实施例中，这项发明涉及制备N-取代哌嗪乙酸活性酯的方法，包括其同位素富集版本。
• Isotopically enriched N-substituted piperazines and methods for the preparation thereof
  申请人：Pappin J.C. Darryl

  公开号：US20050148773A1

  公开（公告）日：2005-07-07

  In some embodiments, this invention pertains to isotopically enriched N-substituted piperazines. In some embodiments, this invention pertains to methods for the preparation of isotopically enriched N-substituted piperazines.

  在某些实施例中，这项发明涉及同位素富集的N-取代哌嗪。在某些实施例中，这项发明涉及同位素富集的N-取代哌嗪的制备方法。